Details of the Drug

General Information of Drug (ID: DM80OZ5)

Drug Name
Halothane
Synonyms
Alotano; Anestan; Bromchlortrifluoraethanum; Bromochlorotrifluoroethane; Chalothane; Fluktan; Fluorotane; Fluothane; Ftorotan; Ftuorotan; Halan; Halotan; Halotano; Halothan; Halothanum; Halsan; Narcotan; Narcotane; Narkotan; Phthorothanum; Rhodialothan; Alotano [DCIT]; Ftorotan [Russian]; CF3CHClBr; Freon 123B1; Fluothane (TN); Halotano [INN-Spanish]; Halothane [Anaesthetics, volatile]; Halothanum [INN-Latin]; Narcotann NE-spofa [Russian]; Narcotann ne-spofa; Halothane [INN:BAN:JAN]; Halothane (JP15/USP/INN); (+-)-2-Bromo-2-chloro-1,1,1-trifluoroethane; 1,1,1-Trifluoro-2-bromo-2-chloroethane; 1,1,1-Trifluoro-2-chloro-2-bromoethane; 1-Bromo-1-chloro-2,2,2-trifluoroethane; 2,2,2-Trifluoro-1-chloro-1-bromoethane; 2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE; 2-Brom-2-chlor-1,1,1-trifluorethan
Indication
Disease Entry ICD 11 Status REF
Anaesthesia 9A78.6 Approved [1], [2]
Therapeutic Class
Anesthetics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 197.38
Topological Polar Surface Area (xlogp) 2.3
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Metabolism
The drug is metabolized via the liver [3]
Chemical Identifiers
Formula
C2HBrClF3
IUPAC Name
2-bromo-2-chloro-1,1,1-trifluoroethane
Canonical SMILES
C(C(F)(F)F)(Cl)Br
InChI
InChI=1S/C2HBrClF3/c3-1(4)2(5,6)7/h1H
InChIKey
BCQZXOMGPXTTIC-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3562
ChEBI ID
CHEBI:5615
CAS Number
151-67-7
DrugBank ID
DB01159
TTD ID
D0D8VE
INTEDE ID
DR0803

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glutamate receptor AMPA (GRIA) TTAN6JD NOUNIPROTAC Antagonist [4]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [5]
Cytochrome P450 2E1 (CYP2E1)
Main DME 		DEVDYN7 CP2E1_HUMAN Substrate [6]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [7]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [5]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [8]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [9]
Microsomal cytochrome MCB5 (CYB5A) DE9A2LB CYB5_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Anaesthesia
ICD Disease Classification 9A78.6
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glutamate receptor AMPA (GRIA) DTT NO-GeName 1.79E-04 -0.69 -0.58
Cytochrome P450 2E1 (CYP2E1) DME CYP2E1 1.87E-04 -1.20E-01 -3.22E-01
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 4.88E-01 -1.69E-05 -1.28E-04
Cytochrome P450 2A6 (CYP2A6) DME CYP2A6 2.02E-01 -2.49E-02 -1.81E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Microsomal cytochrome MCB5 (CYB5A) DME CYB5A 8.92E-01 2.47E-02 8.27E-02
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Halothane
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Halothane and Sevoflurane. Corneal disease [9A76-9A78] [68]
Coadministration of a Drug Treating the Disease Different from Halothane (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Halothane and Ivosidenib. Acute myeloid leukaemia [2A60] [69]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Halothane and Midostaurin. Acute myeloid leukaemia [2A60] [68]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Halothane and Idarubicin. Acute myeloid leukaemia [2A60] [68]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Halothane and Arn-509. Acute myeloid leukaemia [2A60] [70]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Halothane and Gilteritinib. Acute myeloid leukaemia [2A60] [71]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Halothane and Ivabradine. Angina pectoris [BA40] [70]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Halothane and Bepridil. Angina pectoris [BA40] [68]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Halothane and Dronedarone. Angina pectoris [BA40] [68]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Halothane and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [72]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Halothane and Cilostazol. Arterial occlusive disease [BD40] [68]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Halothane and Posaconazole. Aspergillosis [1F20] [68]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Halothane and Levalbuterol. Asthma [CA23] [73]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Halothane and Pirbuterol. Asthma [CA23] [74]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Halothane and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [70]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Halothane and Ofloxacin. Bacterial infection [1A00-1C4Z] [75]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Halothane and Clarithromycin. Bacterial infection [1A00-1C4Z] [68]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Halothane and Sparfloxacin. Bacterial infection [1A00-1C4Z] [75]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Halothane and Retigabine. Behcet disease [4A62] [68]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Halothane and Eribulin. Breast cancer [2C60-2C6Y] [68]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Halothane and Lapatinib. Breast cancer [2C60-2C6Y] [68]
Alpelisib DMEXMYK Moderate Increased metabolism of Halothane caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [70]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Halothane and Bosutinib. Breast cancer [2C60-2C6Y] [70]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Halothane and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [76]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Halothane and Olodaterol. Chronic obstructive pulmonary disease [CA22] [74]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Halothane and Vilanterol. Chronic obstructive pulmonary disease [CA22] [73]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Halothane and Indacaterol. Chronic obstructive pulmonary disease [CA22] [74]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Halothane and Arformoterol. Chronic obstructive pulmonary disease [CA22] [74]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Halothane and Probucol. Coronary atherosclerosis [BA80] [68]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Halothane and Pasireotide. Cushing syndrome [5A70] [68]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Halothane and Osilodrostat. Cushing syndrome [5A70] [70]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Halothane caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [77]
MK-8228 DMOB58Q Moderate Decreased metabolism of Halothane caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [78]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Halothane and Escitalopram. Depression [6A70-6A7Z] [68]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Halothane and Clomipramine. Depression [6A70-6A7Z] [68]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Halothane and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [68]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Halothane and Deutetrabenazine. Dystonic disorder [8A02] [79]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Halothane and Ingrezza. Dystonic disorder [8A02] [80]
Cenobamate DMGOVHA Moderate Increased metabolism of Halothane caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [81]
Rufinamide DMWE60C Moderate Increased metabolism of Halothane caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [70]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Halothane and Solifenacin. Functional bladder disorder [GC50] [68]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Halothane and Sunitinib. Gastrointestinal stromal tumour [2B5B] [68]
Rifapentine DMCHV4I Moderate Increased metabolism of Halothane caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [82]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Halothane and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [83]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Halothane and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [84]
Etravirine DMGV8QU Moderate Increased metabolism of Halothane caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Halothane and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [68]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Halothane and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [68]
Darunavir DMN3GCH Moderate Decreased metabolism of Halothane caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [86]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Halothane and Polyethylene glycol. Irritable bowel syndrome [DD91] [70]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Halothane and Crizotinib. Lung cancer [2C25] [87]
Brigatinib DM7W94S Moderate Increased metabolism of Halothane caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [88]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Halothane and Ceritinib. Lung cancer [2C25] [68]
PF-06463922 DMKM7EW Moderate Increased metabolism of Halothane caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [89]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Halothane and Osimertinib. Lung cancer [2C25] [90]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Halothane and Selpercatinib. Lung cancer [2C25] [70]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Halothane and Lumefantrine. Malaria [1F40-1F45] [91]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Halothane and Halofantrine. Malaria [1F40-1F45] [92]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Halothane and Hydroxychloroquine. Malaria [1F40-1F45] [93]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Halothane and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [70]
Idelalisib DM602WT Moderate Decreased metabolism of Halothane caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [94]
IPI-145 DMWA24P Moderate Decreased metabolism of Halothane caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [95]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Halothane and Arsenic trioxide. Mature B-cell lymphoma [2A85] [96]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Halothane and Vemurafenib. Melanoma [2C30] [68]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Halothane and LGX818. Melanoma [2C30] [97]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Halothane caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [70]
Exjade DMHPRWG Moderate Decreased metabolism of Halothane caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [98]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Halothane and Panobinostat. Multiple myeloma [2A83] [99]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Halothane and Siponimod. Multiple sclerosis [8A40] [91]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Halothane and Fingolimod. Multiple sclerosis [8A40] [68]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Halothane and Ozanimod. Multiple sclerosis [8A40] [100]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Halothane and Romidepsin. Mycosis fungoides [2B01] [68]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Halothane and Nilotinib. Myeloproliferative neoplasm [2A20] [68]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Halothane and Dasatinib. Myeloproliferative neoplasm [2A20] [101]
Prasugrel DM7MT6E Minor Decreased metabolism of Halothane caused by Prasugrel mediated inhibition of CYP450 enzyme. Myocardial infarction [BA41-BA43] [70]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Halothane and Entrectinib. Non-small cell lung cancer [2C25] [91]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Halothane and Levomethadyl Acetate. Opioid use disorder [6C43] [70]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Halothane and Lofexidine. Opioid use disorder [6C43] [68]
Olaparib DM8QB1D Moderate Increased metabolism of Halothane caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [91]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Halothane and Rucaparib. Ovarian cancer [2C73] [68]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Halothane and Triclabendazole. Parasitic worm infestation [1F90] [68]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Halothane and Pimavanserin. Parkinsonism [8A00] [102]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Halothane and Macimorelin. Pituitary gland disorder [5A60-5A61] [103]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Halothane and Lefamulin. Pneumonia [CA40] [104]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Halothane caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [105]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Halothane and Degarelix. Prostate cancer [2C82] [70]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Halothane and ABIRATERONE. Prostate cancer [2C82] [70]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Halothane and Enzalutamide. Prostate cancer [2C82] [70]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Halothane and Relugolix. Prostate cancer [2C82] [70]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Halothane and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [106]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Halothane and Quetiapine. Schizophrenia [6A20] [68]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Halothane and Aripiprazole. Schizophrenia [6A20] [91]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Halothane and Iloperidone. Schizophrenia [6A20] [68]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Halothane and Paliperidone. Schizophrenia [6A20] [68]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Halothane and Amisulpride. Schizophrenia [6A20] [107]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Halothane and Asenapine. Schizophrenia [6A20] [68]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Halothane caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [70]
Larotrectinib DM26CQR Moderate Decreased metabolism of Halothane caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [91]
Armodafinil DMGB035 Minor Increased metabolism of Halothane caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [108]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Halothane and LEE011. Solid tumour/cancer [2A00-2F9Z] [68]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Halothane and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [68]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Halothane and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [70]
Pitolisant DM8RFNJ Moderate Increased metabolism of Halothane caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [70]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Halothane and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [68]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Halothane caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [109]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Halothane and Lenvatinib. Thyroid cancer [2D10] [68]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Halothane and Cabozantinib. Thyroid cancer [2D10] [70]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Halothane and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [110]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Halothane and Propafenone. Ventricular tachyarrhythmia [BC71] [68]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Halothane and Flecainide. Ventricular tachyarrhythmia [BC71] [68]
⏷ Show the Full List of 109 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2401).
2 Benzodiazepine utilisation in Australia: report from a new pharmacoepidemiological database. Aust J Public Health. 1993 Dec;17(4):345-9.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 Reduced inhibition of cortical glutamate and GABA release by halothane in mice lacking the K+ channel, TREK-1. Br J Pharmacol. 2007 Nov;152(6):939-45.
5 Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4. Drug Metab Dispos. 1996 Sep;24(9):976-83.
6 Concordance between trifluoroacetic acid and hepatic protein trifluoroacetylation after disulfiram inhibition of halothane metabolism in rats. Acta Anaesthesiol Scand. 2003 Jul;47(6):765-70.
7 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
8 Halothane-dependent lipid peroxidation in human liver microsomes is catalyzed by cytochrome P4502A6 (CYP2A6). Anesthesiology. 2001 Aug;95(2):509-14.
9 Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003 Oct;13(10):619-26.
10 Modulation of the reductive metabolism of halothane by microsomal cytochrome b5 in rat liver. Biochim Biophys Acta. 1987 Dec 7;926(3):231-8.
11 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
21 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
22 Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
23 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
24 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
25 CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
26 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
27 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
28 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
29 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
30 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
31 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
32 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
33 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
34 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
35 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
36 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
37 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
38 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
39 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
40 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
41 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
42 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
43 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
44 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
45 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
46 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
47 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
48 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
49 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
50 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
51 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
52 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
53 Drugs that may have potential CYP2B6 interactions.
54 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
55 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
56 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
57 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
58 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
59 Eszopiclone: its use in the treatment of insomnia. Neuropsychiatr Dis Treat. 2007 Aug;3(4):441-453.
60 Effects of sevoflurane on carrageenan- and fentanyl-induced pain hypersensitivity in Sprague-Dawley rats. Can J Anaesth. 2009 Feb;56(2):126-35.
61 Enflurane directly depresses glutamate AMPA and NMDA currents in mouse spinal cord motor neurons independent of actions on GABAA or glycine receptors. Anesthesiology. 2000 Oct;93(4):1075-84.
62 Transmembrane residues define the action of isoflurane at the GABAA receptor alpha-3 subunit. Brain Res. 2005 Jan 25;1032(1-2):30-5.
63 Glutamatergic and GABAergic modulations of ultrasonic vocalizations during maternal separation distress in mouse pups. Psychopharmacology (Berl). 2009 May;204(1):61-71.
64 GABA(A) receptor ligands and their therapeutic potentials. Curr Top Med Chem. 2002 Aug;2(8):817-32.
65 Pharmacologic management of Alzheimer disease, Part II: Antioxidants, antihypertensives, and ergoloid derivatives. Ann Pharmacother. 1999 Feb;33(2):188-97.
66 Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des. 2006;12(28):3665-79.
67 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
68 Canadian Pharmacists Association.
69 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
70 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
71 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
72 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
73 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
74 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
75 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
76 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
77 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
78 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
79 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
80 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
81 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
82 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
83 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
84 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
85 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
86 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
87 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
88 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
89 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
90 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
91 Cerner Multum, Inc. "Australian Product Information.".
92 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
93 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
94 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
95 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
96 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
97 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
98 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
99 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
100 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
101 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
102 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
103 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
104 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
105 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
106 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
107 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
108 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
109 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
110 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]